Neurocrine Biosciences, Inc. (0K6R.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 03:35PM BST. Market open.
| Previous close | 139.18 |
| Open | 142.32 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 141.02 - 144.00 |
| 52-week range | 89.66 - 144.00 |
| Volume | |
| Avg. volume | 1,189 |
| Market cap | 139.952M |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 1.95 |
| EPS (TTM) | 0.73 |
| Earnings date | 30 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations
Neurocrine Biosciences ( NASDAQ:NBIX ) First Quarter 2024 Results Key Financial Results Revenue: US$515.3m (up 23% from...
- GuruFocus.com
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
INGREZZA drives strong sales while new drug approvals and a solid cash position underscore a promising future.
GuruFocus.comDecoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
Financial Performance and Market Dynamics: A SWOT Analysis of Neurocrine Biosciences Inc
© 2024 Yahoo. All rights reserved.